The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of Cancer

Ryan Quiroz, Michael H. Reutershan, Sebastian E. Schneider, David Sloman, Brian M. Lacey, Brooke M. Swalm, Charles S. Yeung, Craig Gibeau, Daniel S. Spellman, Danica A. Rankic, Dapeng Chen, David Witter, Doug Linn, Erik Munsell, Guo Feng, Haiyan Xu, Jonathan M. E. Hughes, Jongwon Lim, Josep Sauri, Kristin GeddesMurray Wan, My Sam Mansueto, Nicole E. Follmer, Patrick S. Fier, Phieng Siliphaivanh, Pierre Daublain, Rachel L. Palte, Robert P. Hayes, Sandra Lee, Shuhei Kawamura, Steven Silverman, Sulagna Sanyal, Timothy J. Henderson, Yingchun Ye, Yuanwei Gao, Benjamin Nicholson, Michelle R. Machacek

Producció científica: Article en revista indexadaArticleAvaluat per experts

20 Cites (Scopus)

Fingerprint

Navegar pels temes de recerca de 'The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of Cancer'. Junts formen un fingerprint únic.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Chemistry